Luiz Fábio Silva Ribeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luiz Fábio Silva Ribeiro has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Lucas Rezende de Freitas
Faculty of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil
5 shared publications - Ofonime Chantal Udoma-Udofa
Faculty of Medicine, Federal University of Juiz de Fora, Juiz de Fora, Brazil
4 shared publications - Lucas Kreutz-Rodrigues
Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA
3 shared publications Karim Bakri
Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, United States
2 shared publications- Maísa de Souza Borges
School of Medicine, Faculty of Minas, Belo Horizonte, Brazil
2 shared publications - Pedro Henrique Reginato
Faculty of Medicine, Federal University of Paraná, Curitiba, Brazil
2 shared publications
Latest Publications
- Open Access
- 24 January 2026
- Published by Elsevier in Brazilian Journal of Anesthesiology (English Edition)
- Vol. 76 (3) , 844729
Remimazolam compared with propofol, dexmedetomidine, and midazolam for adult sedation in flexible bronchoscopy: a systematic review and meta-analysis
- 24 January 2026
- Published by Elsevier in Brazilian Journal of Anesthesiology (English Edition)
- Vol. 76 (3) , 844729
Open AccessRemimazolam compared with propofol, dexmedetomidine, and midazolam for adult sedation in flexible bronchoscopy: a systematic review and meta-analysis
- 30 December 2024
- Published by Springer Nature in Neuroradiology
- Vol. 67 (1) , 241-255
Efficacy and safety of tirofiban in acute ischemic stroke due to intracranial atherosclerotic disease for patients undergoing endovascular treatment: a systematic review and meta-analysis
Purpose Tirofiban has emerged as an adjunct therapy for acute ischemic stroke (AIS) patients undergoing endovascular treatment (EVT). However, its benefits for AIS patients with intracranial atherosclerotic disease (ICAD) remains unclear. This meta-analysis evaluates its efficacy and safety in ICAD-related AIS patients undergoing EVT. Methods We searched PubMed, Cochrane, and Embase up to September, 2024, for studies comparing tirofiban to placebo or no intervention in ICAD-related AIS. Primary outcome was modified Rankin Scale (mRS) 0–2 at 90 days. Secondary outcomes included 90-day mRS 0–1, mRS score at 90 days, successful reperfusion, 90-day mortality, postprocedural reocclusion, and symptomatic/non-symptomatic intracranial hemorrhage (ICH). Subgroup analyses evaluated tirofiban administration routes (intravenous, intra-arterial, or combined). Results Thirteen studies comprising 3,572 patients were included. Intravenous tirofiban significantly increased mRS 0–2 (RR 1.26 [95% CI 1.13; 1.42]; p < 0.0001, I²= 0%), mRS 0–1(RR 1.24 [95% CI 1.05; 1.45]; p = 0.0098, I² = 0%), reduced mRS score by 0.58 points ([95% CI -0.99; -0.17]; p = 0.006, I²= 66%) and decreased mortality (RR 0.68 [95% CI 0.57; 0.80]; p < 0.0001, I²= 8%) at 90 days compared to control. Tirofiban overall reduced postprocedural reocclusion relative to control (RR 0.36 [95% CI 0.14; 0.94]; p = 0.036, I²= 73%). No significant differences were observed in successful reperfusion or ICH. Conclusion Intravenous tirofiban demonstrated an efficacy and safety profile, improving functional recovery and reducing mortality. Tirofiban overall reduced postprocedural reocclusion compared to control. No significant differences were found between groups in successful reperfusion or ICH. These findings support tirofiban as a safe and effective EVT adjunct. Systematic review protocol PROSPERO (CRD42024606522)
- 30 December 2024
- Published by Springer Nature in Neuroradiology
- Vol. 67 (1) , 241-255
Efficacy and safety of tirofiban in acute ischemic stroke due to intracranial atherosclerotic disease for patients undergoing endovascular treatment: a systematic review and meta-analysis
Purpose Tirofiban has emerged as an adjunct therapy for acute ischemic stroke (AIS) patients undergoing endovascular treatment (EVT). However, its benefits for AIS patients with intracranial atherosclerotic disease (ICAD) remains unclear. This meta-analysis evaluates its efficacy and safety in ICAD-related AIS patients undergoing EVT. Methods We searched PubMed, Cochrane, and Embase up to September, 2024, for studies comparing tirofiban to placebo or no intervention in ICAD-related AIS. Primary outcome was modified Rankin Scale (mRS) 0–2 at 90 days. Secondary outcomes included 90-day mRS 0–1, mRS score at 90 days, successful reperfusion, 90-day mortality, postprocedural reocclusion, and symptomatic/non-symptomatic intracranial hemorrhage (ICH). Subgroup analyses evaluated tirofiban administration routes (intravenous, intra-arterial, or combined). Results Thirteen studies comprising 3,572 patients were included. Intravenous tirofiban significantly increased mRS 0–2 (RR 1.26 [95% CI 1.13; 1.42]; p < 0.0001, I²= 0%), mRS 0–1(RR 1.24 [95% CI 1.05; 1.45]; p = 0.0098, I² = 0%), reduced mRS score by 0.58 points ([95% CI -0.99; -0.17]; p = 0.006, I²= 66%) and decreased mortality (RR 0.68 [95% CI 0.57; 0.80]; p < 0.0001, I²= 8%) at 90 days compared to control. Tirofiban overall reduced postprocedural reocclusion relative to control (RR 0.36 [95% CI 0.14; 0.94]; p = 0.036, I²= 73%). No significant differences were observed in successful reperfusion or ICH. Conclusion Intravenous tirofiban demonstrated an efficacy and safety profile, improving functional recovery and reducing mortality. Tirofiban overall reduced postprocedural reocclusion compared to control. No significant differences were found between groups in successful reperfusion or ICH. These findings support tirofiban as a safe and effective EVT adjunct. Systematic review protocol PROSPERO (CRD42024606522)